Hi TC,Great question as always. N acetylcystein is an mTORC1...

Hi TC,

Great question as always. N acetylcystein is an mTORC1 inhibitor as with MPL. It's therapeutic effects are milder on the mTOR signalling pathway.
NAC has had off the top of my head 3200 studies completed on a generic drug. Post graduate students love testing it against a full variety of conditions .

Treatment with mTOR inhibitors can be complicated by adverse events. The most frequently occurring adverse events are stomatitis, rash, anemia, fatigue, hyperglycemia ( + blood sugars) decreased appetite, nausea, and diarrhea. Additionally, interstitial lung disease is an adverse event of particular importance.

mTOR inhibition overdose ( this takes many doses) can also cause an immunosuppression syndrome.

Therefore by treating one condition another reaffirms itself.

Its called iatrogenia . Hospital lingo for " O dear we didn't think that drug would do that ".